KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCA Healthcare (HCA) Other Non-Current Assets (2016 - 2025)

HCA Healthcare (HCA) has disclosed Other Non-Current Assets for 16 consecutive years, with $226.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Other Non-Current Assets rose 13.57% to $226.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was $226.0 million, a 13.57% increase, with the full-year FY2024 number at $230.0 million, up 25.0% from a year prior.
  • Other Non-Current Assets was $226.0 million for Q1 2025 at HCA Healthcare, down from $230.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $685.0 million in Q3 2021 to a low of $184.0 million in Q4 2023.
  • A 5-year average of $363.8 million and a median of $298.0 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: plummeted 56.62% in 2023, then increased 25.0% in 2024.
  • HCA Healthcare's Other Non-Current Assets stood at $598.0 million in 2021, then plummeted by 50.17% to $298.0 million in 2022, then plummeted by 38.26% to $184.0 million in 2023, then rose by 25.0% to $230.0 million in 2024, then fell by 1.74% to $226.0 million in 2025.
  • Per Business Quant, the three most recent readings for HCA's Other Non-Current Assets are $226.0 million (Q1 2025), $230.0 million (Q4 2024), and $240.0 million (Q2 2024).